Try our mobile app

Switch to company model in classical logic    *

General information

Country: GERMANY

Sector: Biotechnology

Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company`s therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment of treatment-resistant depression (TRD); RL-007, a cholinergic, glutamatergic, and GABA-B receptor modulator to treat cognitive impairment associated with schizophrenia; DMX-1002, an oral formulation of ibogaine for treating opioid use disorder (OUD); GRX-917, an oral formulation of a deuterated version of etifoxine for the generalized anxiety disorder treatment; and NN-101, a novel intranasal formulation of N-acetylcysteine to treat mild traumatic brain injuries. Its therapeutic candidates also comprise VLS-01, a formulation of N,N-dimethyltryptamine for treating TRD; EMP-01, an oral formulation of an 3,4-methyl enedioxy methamphetamine for the treatment of post-traumatic stress disorder; RLS-01, a formulation of Salvinorin A for TRD; KUR-101, an oral formulation of deuterated mitragynine to treat OUD; and DMX-1001, an oral formulation of noribogaine for the treatment of OUD. The company was formerly known as Adripa Holding B.V. Atai Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Website: atai.life



Growth: Bad revenue growth rate -95.0%, there is acceleration compared to average historical growth rates -100.0%

Profitability: LTM EBITDA margin is negative, 0.0%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.01 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -142.7% (LTM)

Entry Point: Share price is 45.2% higher than minimum and 73.3% lower than maximum for the last 3 years

Insiders: For the last 3 months insiders bought company shares on $22.8 mln (6.741% of cap.)

Key Financials (Download financials)

Ticker: ATAI
Share price, USD:  (-3.8%)1.51
year average price 1.5538  


year start price 2.1000 2024-03-09

max close price 2.6000 2024-04-08

min close price 1.0600 2024-10-03

current price 1.5100 2025-03-08
Common stocks: 160 732 988

Dividend Yield:  0.0%
EV / Sales: 200.0x
Margin (EBITDA LTM / Revenue): 0.0%
Fundamental value created in LTM:
Market Cap ($m): 252
Net Debt ($m): -123
EV (Enterprise Value): 129
Price to Book: 1.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-03-05proactiveinvestors.com

atai Life Sciences-backed trial in treatment-resistant depression completes patient enrollment

2025-02-27seekingalpha.com

Atai: Following The Path That Spravato Laid And Moving Beyond It

2025-02-20proactiveinvestors.com

atai Life Sciences completes public offering, raising $63.25M

2025-02-13proactiveinvestors.com

atai Life Sciences announces pricing of $55M public offering of shares

2025-02-12globenewswire.com

atai Life Sciences Announces Pricing of Public Offering of Common Shares

2025-02-12proactiveinvestors.com

atai Life Sciences unveils $55M public offering to advance mental health treatments

2025-02-12globenewswire.com

atai Life Sciences Announces Proposed Public Offering of Common Shares

2025-02-08proactiveinvestors.com

atai Life Sciences CEO discusses success of BPL-003 alcohol use disorder trial - ICYMI

2025-02-06proactiveinvestors.com

atai Life Sciences-backed psychedelic drug could offer superior value, analysts believe

2025-02-03proactiveinvestors.com

atai Life Sciences gains as new data derisks upcoming treatment-resistant depression trial readout
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ATAI ATAI ATAI ATAI ATAI ATAI ATAI ATAI ATAI
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-14 2024-08-13 2024-05-15 2024-03-28 2023-11-14 2023-08-10 2023-05-11 2023-03-24 2022-11-10
acceptedDate 2024-11-14 16:36:32 2024-08-13 16:27:19 2024-05-15 07:53:10 2024-03-28 16:49:18 2023-11-14 16:17:19 2023-08-10 16:17:00 2023-05-11 16:18:02 2023-03-24 16:38:14 2022-11-10 07:31:50
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 40 000 273 000 0 18 000 87 000 172 000 37 000 38 000 24 000
costOfRevenue 0 82 000 83 000 101 000 74 000 195 000 0 0 0
grossProfit 40 000 191 000 -83 000 -83 000 13 000 -23 000 37 000 38 000 24 000
grossProfitRatio 1 0.7 0 -4.611 0.149 -0.134 1 1 1
researchAndDevelopmentExpenses 12M 13M 11M 14M 13M 15M 19M 22M 19M
generalAndAdministrativeExpenses 10M 13M 13M 19M 14M 17M 14M 16M 19M
sellingAndMarketingExpenses 0 0 -1 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 10M 13M 12M 19M 14M 17M 14M 16M 19M
otherExpenses 0 0 -5000 -111 000 71M 204 000 58 000 -2M 0
operatingExpenses 23M 26M 24M 33M 27M 32M 33M 38M 38M
costAndExpenses 23M 26M 24M 34M 27M 32M 33M 38M 38M
interestIncome 160 000 118 000 307 000 656 000 612 000 303 000 275 000 187 000 145 000
interestExpense 783 000 702 000 687 000 691 000 686 000 658 000 622 000 -243 000 145 000
depreciationAndAmortization 83 000 82 000 83 000 101 000 74 000 79 000 -680 000 53 000 -5M
ebitda -23M -57M -24M -33M -27M -32M -33M -38M -44M
ebitdaratio -565.05 -207.597 0 -1858.889 -308.437 -185.244 -897.676 -988.553 -1817.958
operatingIncome -23M -26M -24M -34M -27M -32M -33M -38M -38M
operatingIncomeRatio -565.05 -94.245 0 -1864.5 -308.437 -185.244 -879.297 -988.553 -1600.958
totalOtherIncomeExpensesNet -4M -32M -2M 15M 71M 204 000 -622 000 -2M 5M
incomeBeforeTax -26M -57M -26M -18M 44M -32M -33M -39M -33M
incomeBeforeTaxRatio -661.575 -210.073 0 -1017.778 503.989 -184.058 -896.108 -1034.763 -1380.583
incomeTaxExpense -178 000 19 000 -4000 428 000 238 000 185 000 165 000 6M 135 000
netIncome -26M -57M -27M -18M 44M -33M -33M -45M -33M
netIncomeRatio -657.15 -209.934 0 -1016.222 508.552 -192.105 -900.568 -1192.711 -1386.208
eps -0.16 -0.36 -0.17 -0.12 0.28 -0.21 -0.21 -0.29 -0.21
epsdiluted -0.16 -0.36 -0.17 -0.12 0.28 -0.21 -0.21 -0.29 -0.21
weightedAverageShsOut 161M 160M 159M 159M 156M 156M 156M 159M 157M
weightedAverageShsOutDil 161M 160M 159M 159M 156M 156M 156M 159M 157M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ATAI ATAI ATAI ATAI ATAI ATAI ATAI ATAI ATAI
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-14 2024-08-13 2024-05-15 2024-03-28 2023-11-14 2023-08-10 2023-05-11 2023-03-24 2022-11-10
acceptedDate 2024-11-14 16:36:32 2024-08-13 16:27:19 2024-05-15 07:53:10 2024-03-28 16:49:18 2023-11-14 16:17:19 2023-08-10 16:17:00 2023-05-11 16:18:02 2023-03-24 16:38:14 2022-11-10 07:31:50
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 30M 19M 24M 45M 76M 141M 186M 191M 143M
shortTermInvestments 15M 69M 87M 109M 133M 86M 64M 82M 162M
cashAndShortTermInvestments 45M 103M 111M 154M 209M 227M 250M 273M 304M
netReceivables 6M 12M 2M 2M 2M 9M 9M 0 5M
inventory 0 0 2 1 0 0 0 0 0
otherCurrentAssets 63M 2M 4M 29M 7M 6M 9M 14M 1M
totalCurrentAssets 114M 118M 118M 186M 217M 243M 268M 287M 317M
propertyPlantEquipmentNet 2M 2M 2M 2M 2M 2M 3M 928 000 728 000
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 45M 94M 147M 103M 75M 4M 6M 7M 8M
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 36M 2M 3M 3M 13M 4M 4M 11M 16M
totalNonCurrentAssets 83M 98M 152M 108M 91M 11M 13M 18M 25M
otherAssets 0 0 0 0 0 0 0 0 0
totalAssets 198M 216M 269M 293M 308M 254M 281M 305M 343M
accountPayables 5M 4M 4M 5M 6M 4M 5M 2M 4M
shortTermDebt 3M 478 000 244 000 275 000 292 000 322 000 317 000 0 0
taxPayables 182 000 346 000 695 000 715 000 887 000 808 000 2M 2M 7M
deferredRevenue 0 0 -4M 715 002 13M 13M 0 0 0
otherCurrentLiabilities 12M 13M 15M 15M 889 000 890 000 16M 17M 22M
totalCurrentLiabilities 20M 18M 15M 20M 20M 18M 21M 20M 26M
longTermDebt 21M 19M 15M 15M 16M 16M 16M 15M 15M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 10M 10M 16M 14M 4M 4M 240M 265M 17M
totalNonCurrentLiabilities 32M 30M 31M 29M 20M 20M 256M 281M 21M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 1M 1M 907 000 990 000 1M 1M 2M 0 0
totalLiabilities 51M 47M 46M 49M 40M 38M 277M 300M 47M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 19M 19M 19M 19M 19M 19M 19M 19M 19M
retainedEarnings -661M -635M -578M -551M -533M -577M -544M -510M -465M
accumulatedOtherComprehensiveIncomeLoss -20M -19M -19M -19M -19M -21M -21M -22M -26M
othertotalStockholdersEquity 808M 803M 801M 795M 799M 792M 546M 774M 762M
totalStockholdersEquity 146M 168M 223M 243M 266M 213M -546M 261M 289M
totalEquity 146M 169M 223M 244M 269M 216M -542M 261M 289M
totalLiabilitiesAndStockholdersEquity 198M 216M 269M 293M 308M 254M 281M 305M 343M
minorityInterest 596 000 643 000 713 000 1M 2M 3M 4M 5M 0
totalLiabilitiesAndTotalEquity 198M 216M 269M 293M 308M 254M 281M 305M 343M
totalInvestments 60M 163M 234M 212M 72M 4M 70M 89M 170M
totalDebt 24M 20M 16M 16M 17M 17M 17M 15M 15M
netDebt -6M 299 000 -7M -29M -60M -124M -169M -175M -128M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol ATAI ATAI ATAI ATAI ATAI ATAI ATAI ATAI ATAI
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-14 2024-08-13 2024-05-15 2024-03-28 2023-11-14 2023-08-10 2023-05-11 2023-03-24 2022-11-10
acceptedDate 2024-11-14 16:36:32 2024-08-13 16:27:19 2024-05-15 07:53:10 2024-03-28 16:49:18 2023-11-14 16:17:19 2023-08-10 16:17:00 2023-05-11 16:18:02 2023-03-24 16:38:14 2022-11-10 07:31:50
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -27M -57M -27M -18M 43M -34M -34M -47M -36M
depreciationAndAmortization 83 000 82 000 83 000 101 000 74 000 79 000 65 000 53 000 36 000
deferredIncomeTax 0 0 0 -8M -71M 1M 0 5M 0
stockBasedCompensation 5M 6M 6M 7M 8M 9M 9M 12M 11M
changeInWorkingCapital 2M 3M -5M 3M 341 000 831 000 4M -4M 34 000
accountsReceivables 0 0 -1 000 000 -2M 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables 1M -18 946 -742 000 -990 087 2M -1M 2M -598 000 155 000
otherWorkingCapital 1M 3M -4M 4M -1M 2M -2M -3M -121 000
otherNonCashItems 437 529 32M 10M -4M 416 000 81 000 856 000 3M -3M
netCashProvidedByOperatingActivities -19M -16M -23M -21M -18M -23M -21M -31M -28M
investmentsInPropertyPlantAndEquipment 5000 0 -5000 -10 037 -2000 -128 000 -443 000 -223 000 -529 000
acquisitionsNet 0 0 0 37 000 2000 157 000 0 171M 0
purchasesOfInvestments 97M -66M -31M -5M -138M -40M 0 -53M -27M
salesMaturitiesOfInvestments -56M 84M 44M 7M 94M 18M 19M 133M 0
otherInvestingActivites -16M -2M -1M -2M -2M -157 000 -3M -171M 94M
netCashUsedForInvestingActivites 25M 16M 11M -189 282 -46M -22M 16M 80M 66M
debtRepayment 0 0 0 -8M -44.984 -100 717 0 0 0
commonStockIssued -324 697 324 697 0 16 429 -92.666 1478.223 206 000 5M 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 5M 326 000 0 -8M 89.967 -761.223 0 -6M 20M
netCashUsedProvidedByFinancingActivities 5M 326 000 0 -8M -47.683 -100 000 206 000 -922 000 20M
effectOfForexChangesOnCash 237 000 66 000 -64 000 -212 000 318 000 -76 000 159 000 -551 000 621 000
netChangeInCash 11M 466 000 -21M -31M -65M -45M -5M 48M 58M
cashAtEndOfPeriod 45M 34M 24M 45M 76M 141M 186M 191M 143M
cashAtBeginningOfPeriod 34M 34M 45M 76M 141M 186M 191M 143M 84M
operatingCashFlow -19M -16M -23M -21M -18M -23M -21M -31M -28M
capitalExpenditure -1000 0 -5000 -10 037 -2000 -128 000 -443 000 -223 000 -529 000
freeCashFlow -19M -16M -23M -21M -18M -23M -22M -31M -29M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2022 q3
2022-11-11 ET (fiscal 2022 q3)
2022 q2
2022-08-15 ET (fiscal 2022 q2)
2022 q1
2022-05-16 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-13 13:00 ET
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
2024-10-15 12:00 ET
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
2024-09-04 11:00 ET
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
2024-08-13 11:10 ET
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
2024-08-13 11:00 ET
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
2024-08-07 11:00 ET
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
2024-06-26 11:00 ET
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
2024-06-26 10:09 ET
atai Life Sciences co-CEO says initial results from ELE-101 show promise in treating depression
2024-06-20 11:00 ET
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
2024-05-31 11:00 ET
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
2024-05-23 11:00 ET
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
2024-05-15 10:59 ET
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
2024-04-24 11:00 ET
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
2024-04-17 11:00 ET
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
2024-03-28 11:00 ET
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
2024-03-27 11:00 ET
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
2024-03-12 16:35 ET
atai Life Sciences advances VLS-01 for treatment-resistant depression
2024-03-04 13:00 ET
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
2024-02-28 22:00 ET
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
2024-02-06 22:00 ET
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
2024-01-04 12:00 ET
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
2024-01-02 13:00 ET
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
2023-11-14 12:03 ET
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
2023-10-17 12:00 ET
Cognito Therapeutics Appoints Greg Weaver as Chief Financial Officer
2023-10-06 20:05 ET
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
2023-10-02 20:13 ET
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
2023-09-14 12:02 ET
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
2023-09-06 20:01 ET
atai Life Sciences to Participate in Upcoming September Investor Conferences
2023-08-10 10:59 ET
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
2023-08-10 10:59 ET
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
2023-08-08 20:02 ET
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
2023-08-08 20:02 ET
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
2023-06-01 10:59 ET
atai Life Sciences to Participate in Upcoming June Investor Conferences
2023-06-01 10:59 ET
atai Life Sciences to Participate in Upcoming June Investor Conferences
2023-05-11 10:59 ET
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
2023-05-11 10:59 ET
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
2023-05-02 21:20 ET
atai Life Sciences to Participate in Upcoming May Investor Conference
2023-05-02 21:20 ET
atai Life Sciences to Participate in Upcoming May Investor Conference
2023-04-28 10:59 ET
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
2023-04-28 10:59 ET
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
2023-04-13 10:59 ET
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
2023-04-13 10:59 ET
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
2023-03-24 10:59 ET
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
2023-03-24 10:59 ET
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
2023-03-06 12:00 ET
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
2023-03-06 12:00 ET
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
2023-03-01 21:01 ET
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
2023-03-01 21:01 ET
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
2023-01-17 10:00 ET
Trippy Trading: Top Psychedelic Stocks For 2023
2023-01-09 11:59 ET
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
2023-01-09 11:59 ET
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
2023-01-06 12:00 ET
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
2023-01-06 12:00 ET
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
2022-12-23 11:59 ET
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
2022-12-23 11:59 ET
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
2022-12-19 11:59 ET
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
2022-12-19 11:59 ET
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
2022-12-16 15:00 ET
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
2022-12-16 15:00 ET
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
2022-11-29 11:59 ET
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
2022-11-29 11:59 ET
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
2022-11-17 12:00 ET
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
2022-11-17 12:00 ET
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
2022-11-10 11:59 ET
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
2022-11-10 11:59 ET
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
2022-11-05 13:00 ET
Microdose Announces The Second Annual Microdose Awards Winners
2022-11-04 13:35 ET
Women in Psychedelics Announces atai as Platinum Sponsors
2022-11-01 16:00 ET
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
2022-11-01 16:00 ET
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
2022-11-01 11:00 ET
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
2022-11-01 11:00 ET
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
2022-10-25 11:03 ET
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
2022-10-25 11:03 ET
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
2022-10-20 10:59 ET
atai Life Sciences Announces R&D Day Agenda
2022-10-20 10:59 ET
atai Life Sciences Announces R&D Day Agenda
2022-10-19 17:46 ET
Microdose Announces the Latest Round of Keynotes, Celebrity Guests and Featured Speakers for the 2nd Edition of Wonderland
2022-10-18 11:00 ET
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
2022-10-18 11:00 ET
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
2022-10-13 13:21 ET
IntelGenx’s Collaboration with atai Life Sciences Culminates in the Initiation of First-in-Human Clinical Study of an Oral Thin Film Psychedelic Drug Candidate
2022-10-12 11:00 ET
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
2022-10-12 11:00 ET
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
2022-10-05 11:00 ET
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
2022-10-05 11:00 ET
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
2022-10-04 11:00 ET
atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day
2022-10-04 11:00 ET
atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day
2022-09-27 12:00 ET
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
2022-09-27 12:00 ET
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
2022-09-06 22:30 ET
atai Life Sciences to Participate in September Investor Events
2022-09-06 22:30 ET
atai Life Sciences to Participate in September Investor Events
2022-08-15 11:35 ET
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update
2022-08-15 11:35 ET
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update
2022-08-15 10:55 ET
atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital
2022-08-15 10:55 ET
atai Life Sciences Secures Term Loan Facility for up to $175 Million from Hercules Capital
2022-08-01 10:59 ET
atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update
2022-08-01 10:59 ET
atai Life Sciences to Announce Second Quarter 2022 Financial Results and Business Update
2022-06-30 10:59 ET
atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer
2022-06-30 10:59 ET
atai Life Sciences Company Kures Therapeutics Appoints Dr. Chad Beyer as Chief Executive Officer
2022-06-17 10:59 ET
Stephen Bardin to Join atai Life Sciences as CFO Designate
2022-06-17 10:59 ET
Stephen Bardin to Join atai Life Sciences as CFO Designate
2022-06-16 09:59 ET
atai Life Sciences to Participate in Upcoming June Healthcare Conferences
2022-06-16 09:59 ET
atai Life Sciences to Participate in Upcoming June Healthcare Conferences
2022-05-16 10:55 ET
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update
2022-05-16 10:55 ET
atai Life Sciences Reports First Quarter 2022 Financial Results and Business Update
2022-05-05 19:19 ET
CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update
2022-05-05 19:19 ET
CORRECTION - atai Life Sciences to Announce First Quarter 2022 Financial Results and Business Update
2022-05-04 08:00 ET
atai Life Sciences to Announce First-Quarter 2022 Financial Results
2022-05-04 08:00 ET
atai Life Sciences to Announce First-Quarter 2022 Financial Results
2022-04-19 16:26 ET
atai Life Sciences to Participate in Upcoming April Investor Conference
2022-04-19 16:26 ET
atai Life Sciences to Participate in Upcoming April Investor Conference
2022-03-30 10:59 ET
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
2022-03-30 10:59 ET
atai Life Sciences Announces Fourth Quarter and Full Year 2021 Financial Results, Reports on R&D Progress and Highlights Strategic Focus Areas of its Innovative Mental Health Platform
2022-03-23 10:59 ET
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
2022-03-23 10:59 ET
atai Life Sciences to Host Conference Call and Webcast to Discuss Results for the Fourth Quarter and Full Year 2021 and Corporate Update
2022-03-21 17:07 ET
atai Life Sciences to Participate in Upcoming March Investor Conferences
2022-03-21 17:07 ET
atai Life Sciences to Participate in Upcoming March Investor Conferences
2022-02-16 11:59 ET
atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine
2022-02-16 11:59 ET
atai Impact Donates to the Multidisciplinary Association for Psychedelic Studies (MAPS) to Support Pioneering Work in Psychedelic Medicine
2022-02-15 11:59 ET
atai Life Sciences to Participate in Upcoming February Investor Conference
2022-01-27 12:05 ET
Dalriada Drug Discovery to Collaborate with atai Life Sciences' New Platform Company to Discover Next-Generation Therapies for Mental Health
2022-01-27 11:59 ET
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
2022-01-27 11:59 ET
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
2022-01-12 11:59 ET
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
2022-01-12 11:59 ET
atai Life Sciences announces FDA Investigational New Drug (IND) Clearance for PCN-101 R-ketamine Program
2022-01-10 18:03 ET
atai Life Sciences to Participate in Upcoming January Investor Conference
2021-12-16 11:59 ET
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics
2021-12-16 11:59 ET
atai Impact Establishes the atai Fellowship Fund in Psychedelic Neuroscience with Massachusetts General Hospital’s Center for the Neuroscience of Psychedelics
2021-12-15 11:57 ET
Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements
2021-12-15 11:57 ET
Apeiron and Other Key Shareholders of atai Life Sciences Reinforce Support by Entering into Extended, Voluntary Share Lock-up Agreements
2021-12-14 12:30 ET
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia
2021-12-14 12:30 ET
atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial of RL-007 in Cognitive Impairment Associated with Schizophrenia
2021-12-13 11:59 ET
atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index
2021-12-13 11:59 ET
atai Life Sciences Has Been Selected for Addition to the NASDAQ Biotechnology Index
2021-12-09 15:30 ET
atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai's supply chain
2021-12-09 15:30 ET
atai Life Sciences launches TryptageniX to further expand atai’s robust intellectual property portfolio and strengthen atai's supply chain
2021-11-29 12:00 ET
atai Life Sciences Increases its Ownership Position in COMPASS Pathways
2021-11-29 12:00 ET
atai Life Sciences Increases its Ownership Position in COMPASS Pathways
2021-11-15 11:59 ET
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
2021-11-15 11:59 ET
atai Life Sciences Reports Third Quarter 2021 Financial Results and Corporate Update
2021-11-08 13:30 ET
atai Life Sciences to Host Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Business Update
2021-11-06 19:54 ET
DemeRx Inc. to Present at Wonderland Miami by Microdose
2021-11-05 20:30 ET
atai Life Sciences to Participate in Upcoming November Investor Conferences
2021-11-01 13:00 ET
atai Life Sciences Announces Supportive Interim Data from First 8-Patient Cohort of Phase 2a Trial for Novel Treatment of Cognitive Impairment Associated with Schizophrenia
2021-10-19 11:00 ET
atai Life Sciences Launches atai Impact, a Philanthropic Program to Harness the Power of Innovative Mental Health Approaches for Positive Social Change
2021-10-11 12:00 ET
atai Life Sciences announces the launch of PsyProtix, to develop a precision psychiatry approach for Treatment-Resistant Depression (TRD)
2021-09-21 12:00 ET
DemeRx Doses First Subject in Phase 1/2a Study of DMX-1002 (Ibogaine) in Opioid Use Disorder
2021-09-15 12:10 ET
atai Life Sciences Increases Loan in Principal by US$6m to Support IntelGenx’s Graduation to Toronto Stock Exchange After Positive Early Feasibility Study Data
2021-09-14 12:00 ET
Perception Neuroscience initiates Phase 2a study of PCN-101 (R-ketamine) for treatment resistant depression
2021-09-09 20:30 ET
atai Life Sciences and Introspect Digital Therapeutics to test novel digital therapeutic approach in patients receiving ketamine for treatment resistant depression
2021-09-03 22:00 ET
atai Life Sciences to Participate in Upcoming September Investor Conferences
2021-08-16 11:00 ET
atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update
2021-08-16 11:00 ET
atai Life Sciences Reports Second Quarter 2021 Financial Results and Business Update
2021-08-12 12:50 ET
atai Launches Revixia Life Sciences to Develop Salvinorin A for a Variety of Mental Health Conditions
2021-08-09 22:00 ET
atai Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update
2021-08-09 22:00 ET
atai Life Sciences to Host Conference Call and Webcast to Discuss Second Quarter 2021 Financial Results and Provide Business Update
2021-08-06 22:10 ET
atai Life Sciences to Present at the 41st Annual Canaccord Genuity Growth Conference
2021-07-28 13:11 ET
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
2021-07-28 13:11 ET
atai Life Sciences launches InnarisBio, in partnership with the University of Queensland, with the aim to develop a more effective nose-to-brain delivery method for atai’s platform of mental health therapeutic programs
2021-07-15 13:00 ET
Leading U.S.-Based Psychedelic Healthcare VC Fund Launches with $35 Million Raised to Tackle the Growing Global Mental Health Crisis
2021-07-07 23:47 ET
atai Life Sciences to Present at the Cowen Psychedelics & Novel Mechanisms in Neuropsychiatry Summit
2021-06-18 03:21 ET
atai Life Sciences Announces Pricing of Upsized Initial Public Offering

SEC forms

Show financial reports only

SEC form 10
2024-11-13 17:25 ET
Atai Life Sciences N.V. reported for 2024 q3
SEC form 8
2024-11-13 08:19 ET
Atai Life Sciences N.V. published news for 2024 q3
SEC form 8
2024-11-13 08:19 ET
Atai Life Sciences N.V. reported for 2024 q3
SEC form 8
2024-11-13 08:19 ET
Atai Life Sciences N.V. published news for 2024 q3
SEC form 10
2024-11-13 00:00 ET
Atai Life Sciences N.V. reported for 2024 q3
SEC form 10
2024-08-13 16:27 ET
Atai Life Sciences N.V. reported for 2024 q2
SEC form 8
2024-08-13 07:23 ET
Atai Life Sciences N.V. published news for 2024 q2
SEC form 8
2024-08-13 07:23 ET
Atai Life Sciences N.V. reported for 2024 q2
SEC form 10
2024-08-13 00:00 ET
Atai Life Sciences N.V. reported for 2024 q2
SEC form 10
2024-05-15 07:53 ET
Atai Life Sciences N.V. reported for 2024 q1
SEC form 8
2024-05-15 07:15 ET
Atai Life Sciences N.V. published news for 2024 q1
SEC form 8
2024-05-15 07:15 ET
Atai Life Sciences N.V. published news for 2024 q1
SEC form 8
2024-05-15 07:15 ET
Atai Life Sciences N.V. published news for 2024 q1
SEC form 10
2024-05-15 00:00 ET
Atai Life Sciences N.V. reported for 2024 q1
SEC form 10
2024-03-28 16:49 ET
Atai Life Sciences N.V. reported for 2023 q4
SEC form 8
2024-03-28 07:20 ET
Atai Life Sciences N.V. reported for 2023 q4
SEC form 8
2024-03-28 07:20 ET
Atai Life Sciences N.V. published news for 2023 q4
SEC form 10
2024-03-28 00:00 ET
Atai Life Sciences N.V. reported for 2023 q4
SEC form 10
2023-11-14 16:17 ET
Atai Life Sciences N.V. reported for 2023 q3
SEC form 8
2023-11-14 07:29 ET
Atai Life Sciences N.V. reported for 2023 q3
SEC form 10
2023-11-14 00:00 ET
Atai Life Sciences N.V. reported for 2023 q3
SEC form 10
2023-08-10 16:17 ET
Atai Life Sciences N.V. reported for 2023 q2
SEC form 6
2023-08-10 07:42 ET
Atai Life Sciences N.V. published news for 2023 q2
SEC form 10
2023-08-10 00:00 ET
Atai Life Sciences N.V. reported for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Atai Life Sciences N.V. published news for 2023 q2
SEC form 10
2023-05-11 16:18 ET
Atai Life Sciences N.V. reported for 2023 q1
SEC form 6
2023-05-11 07:24 ET
Atai Life Sciences N.V. reported for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Atai Life Sciences N.V. reported for 2023 q1
SEC form 10
2023-05-11 00:00 ET
Atai Life Sciences N.V. reported for 2023 q1
SEC form 6
2023-04-28 16:46 ET
Atai Life Sciences N.V. published news for 2023 q1
SEC form 6
2023-04-14 17:01 ET
Atai Life Sciences N.V. published news for 2023 q1
SEC form 10
2023-03-24 16:38 ET
Atai Life Sciences N.V. reported for 2022 q4
SEC form 6
2023-03-24 08:01 ET
Atai Life Sciences N.V. reported for 2022 q4
SEC form 8
2023-03-24 00:00 ET
Atai Life Sciences N.V. reported for 2022 q4
SEC form 10
2023-03-24 00:00 ET
Atai Life Sciences N.V. reported for 2022 q4
SEC form 10
2022-11-10 00:00 ET
Atai Life Sciences N.V. reported for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Atai Life Sciences N.V. reported for 2022 q3
SEC form 8
2022-08-15 00:00 ET
Atai Life Sciences N.V. published news for 2022 q2
SEC form 10
2022-08-15 00:00 ET
Atai Life Sciences N.V. reported for 2022 q2
SEC form 8
2022-05-16 00:00 ET
Atai Life Sciences N.V. reported for 2022 q1
SEC form 10
2022-05-16 00:00 ET
Atai Life Sciences N.V. reported for 2022 q1
SEC form 8
2022-03-30 00:00 ET
Atai Life Sciences N.V. published news for 2021 q4
SEC form 10
2022-03-30 00:00 ET
Atai Life Sciences N.V. published news for 2021 q4
SEC form 8
2021-11-15 00:00 ET
Atai Life Sciences N.V. published news for 2021 q3
SEC form 10
2021-11-15 00:00 ET
Atai Life Sciences N.V. published news for 2021 q3
SEC form 8
2021-08-16 00:00 ET
Atai Life Sciences N.V. published news for 2021 q2